Arthneeti
Acquisition / mergerMajor development· Adverse for the businessFiled on BSE ·

J.B. Chemicals Q4 consolidated net profit 10,137 lakhs vs 14,569 lakhs a year earlier

J B Chemicals & Pharmaceuticals · Pharmaceuticals & Biotechnology

Arthneeti Research DeskPublished 1 min read

Key highlights

  • Consolidated net profit after tax for the quarter ended March 31, 2026 was ₹10,137 lakhs against ₹14,569 lakhs for March 31, 2025; revenue from operations was ₹90,423 lakhs against ₹94,948 lakhs.
  • The quarter includes an exceptional item of ₹2,718 lakhs: severance compensation Rs. 1,872.82 Lakhs and New Labour Codes gratuity cost Rs. 845 lakhs. Board recommended a final dividend of ₹9.30 per share.
  • Shareholders approved the amalgamation with Torrent Pharmaceuticals on April 28, 2026 at 51 shares for every 100 held; a joint petition is filed with NCLT, appointed date January 21, 2026.

Why it's rated major development: the year-on-year change is 30% (20% or more for adverse news)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Board Meeting Outcome for Outcome Of Board Meeting

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from J B Chemicals & Pharmaceuticals

Other acquisition / merger filings this fortnight

All acquisition / merger filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.